Effect of low-dose gemcitabine on unresectable pancreatic cancer in elderly patients

Digestion

Volumn 84, Issue 3, 2011, Pages 230-235

  Matsumoto, Kazuyuki ^a,b   Miyake, Yasuhiro ^a   Kato, Hironari ^a   Kawamoto, Hirofumi ^a   Imagawa, Atsushi ^b   Toyokawa, Tatsuya ^b   Nakatsu, Morihito ^b   Ando, Masaharu ^b   Hirohata, Mamoru ^b   Yamamoto, Kazuhide ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b Mitoyo General Hospital   (Japan)

Author keywords

Age; Best supportive care; Gemcitabine; Pancreatic cancer; Prognosis; Survival

Indexed keywords

CA 19-9 ANTIGEN; GEMCITABINE;

AGED; ANEMIA; ANOREXIA; CANCER SURVIVAL; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; ELDERLY CARE; HUMAN; KARNOFSKY PERFORMANCE STATUS; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PANCREAS CANCER; PNEUMONIA; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; REVIEW; THROMBOCYTOPENIA; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; DEOXYCYTIDINE; DISEASE PROGRESSION; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; NEOPLASM METASTASIS; NEOPLASM STAGING; PANCREATIC NEOPLASMS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 80051787562     PISSN: 00122823     EISSN: 14219867     Source Type: Journal    
DOI: 10.1159/000330384     Document Type: Review

References (17)

1. World Health Organization: The global burden of disease 2004 update. http://www.who. int/healthinfo/global-burden-disease/GBD-report-2004update-full. pdf (accessed September 21, 2010).
2. World Health Organization: Projections of mortality and burden of disease, 2002-2030. http://www.who.int/healthinfo/global-burden-disease/ projections/en/index.html (accessed September 21, 2010).
3. Stathis A, Moore MJ: Advanced pancreatic carcinoma: current treatment and future challenges. Nat Rev Clin Oncol 2010; 7: 163-172.
4. Matsuda T, Marugame T, Kamo KI, Katanoda K, Ajiki W, Sobue T, Japan Cancer Surveillance Research Group: Cancer incidence and incidence rates in Japan in 2005 based on data from 12 population-based cancer registries in the Monitoring of Cancer Incidence in Japan (MCIJ) Project. Jpn J Clin Oncol 2010, in press.
5. Yamagishi Y, Higuchi H, Izumiya M, Sakai G, Iizuka H, Nakamura S, Adachi M, Hozawa S, Takaishi H, Hibi T: Gemcitabine as first-line chemotherapy in elderly patients with unresectable pancreatic carcinoma. J Gastroenterol 2010; 45: 1146-1154.
6. Maréchal R, Demols A, Gay F, de Maertelaer V, Arvanitaki M, Hendlisz A, Van Laethem JL: Tolerance and efficacy of gemcitabine and gemcitabine-based regimens in elderly patients with advanced pancreatic cancer. Pancreas 2008; 36:e16-e21. (Pubitemid 351440948)
7. Yeo TP, Hruban RH, Leach SD, Wilentz RE, Sohn TA, Kern SE, Iacobuzio-Donahue CA, Maitra A, Goggins M, Canto MI, Abrams RA, Laheru D, Jaffee EM, Hidalgo M, Yeo CJ: Pancreatic cancer. Curr Probl Cancer 2002; 26: 176-275.
8. Ando M, Ando Y, Hasegawa Y, Shimokata K, Minami H, Wakai K, Ohno Y, Sakai S: Prognostic value of performance status assessed by patients themselves, nurses, and oncologists in advanced non-small cell lung cancer. Br J Cancer 2001; 85: 1634-1639. (Pubitemid 34081505)
9. Sobin LH, Wittekind C: UICC-TNM Classification of Malignant Tumours, ed 6. New York, Wiley-Liss, 2002.
10. CTC Version 2.0 Publish Data: April 30, 1999. http://ctep.cancer.gov/ protocoldevelopment/electronic-applications/docs/ctcv20-4-30-992.pdf (accessed September 21, 2010).
11. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216.
12. Hanada K, Hino F, Amano H, Fukuda T, Kuroda Y: Current treatment strategies for pancreatic cancer in the elderly. Drugs Aging 2006; 23: 403-410. (Pubitemid 44050426)
13. Weber A, Kehl V, Mittermeyer T, Herberich E, Röthling N, Schmid RM, Prinz C: Prognostic factors for survival in patients with unresectable pancreatic cancer. Pancreas 2010; 39: 1247-1253.
14. Heinemann V, Boeck S, Hinke A, Labianca R, Louvet C: Meta-Analyses of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer. BMC Cancer 2008; 8: 82.
15. Krishnan S, Rana V, Janjan NA, Abbruzzese JL, Gould MS, Das P, Delclos ME, Palla S, Guha S, Varadhachary G, Evans DB, Wolff RA, Crane CH: Prognostic factors in patients with unresectable locally advanced pancreatic adenocarcinoma treated with chemoradiation. Cancer 2006; 107: 2589-2596. (Pubitemid 44845612)
16. Hess V, Glimelius B, Grawe P, Dietrich D, Bodoky G, Ruhstaller T, Bajetta E, Saletti P, Figer A, Scheithauer W, Herrmann R: CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial. Lancet Oncol 2008; 9: 132-138.
17. Koprowski H, Herlyn M, Steplewski Z, Sears HF: Specific antigen in serum of patients with colon carcinoma. Science 1981; 212: 53-55. (Pubitemid 11114676)